primary lung cancer
Conditions
Interventions
In patients with advanced or recurrent lung cancer, intra-venous injections of alpha-GalactosylCeramide pulsed DCs are performed at 1, 2, 7 and 8 weeks after the entry.
Sponsors
Department of Thoracic Surgery, Graduate School of Medicine, Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: patients had received no chemotherapy or radiotherapy for at least 6 weeks before enrollment. patients with a histologic or cytological diagnosis of non-small cell lung cancer, life-expectancy is more than 6 months, Performance status 0-1, Normal bone marrow, liver and renal functions, NKT cells are detected at least 10 cells in 1 mL of peripheral blood
Exclusion criteria
Exclusion criteria: the presence of active infection; a history of hepatitis; a positive response for hepatitis B surface antigen, or human immunodeficiency virus (HIV), hepatitis C virus, or human T-lymphotrophic virus antibodies; evedence for other malignant diseases; serious cardiac disease, recieived concurrent corticosteroid therapy; pregnancy or lactation; been judged to be inappropriate to participate in this study by principle investigator or co-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological response and Clinical response | — |
Countries
Japan
Contacts
Public ContactShinichiro Motohashi
Graduate School of Medicine, Chiba University Department of Thoracic Surgery
Outcome results
None listed